{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T09:00:18Z","timestamp":1791882018698,"version":"4.3.4"},"reference-count":68,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,5,18]],"date-time":"2022-05-18T00:00:00Z","timestamp":1652832000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,5,18]],"date-time":"2022-05-18T00:00:00Z","timestamp":1652832000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100016930","name":"Ferring Research Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100016930","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000057","name":"National Institute of General Medical Sciences","doi-asserted-by":"publisher","award":["P20 GM113126"],"award-info":[{"award-number":["P20 GM113126"]}],"id":[{"id":"10.13039\/100000057","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Interstitial cystitis\/bladder pain syndrome (IC\/BPS) is a chronic and debilitating pain disorder of the bladder and urinary tract with poorly understood etiology. A definitive diagnosis of IC\/BPS can be challenging because many symptoms are shared with other urological disorders. An analysis of urine presents an attractive and non-invasive resource for monitoring and diagnosing IC\/BPS. The antiproliferative factor (APF) peptide has been previously identified in the urine of IC\/BPS patients and is a proposed biomarker for the disorder. Nevertheless, other small urinary peptides have remained uninvestigated in IC\/BPS primarily because protein biomarker discovery efforts employ protocols that remove small endogenous peptides. The purpose of this study is to investigate the profile of endogenous peptides in IC\/BPS patient urine, with the goal of identifying putative peptide biomarkers. Here, a non-targeted peptidomics analysis of urine samples collected from IC\/BPS patients were compared to urine samples from asymptomatic controls. Our results show a general increase in the abundance of urinary peptides in IC\/BPS patients, which is consistent with an increase in inflammation and protease activity characteristic of this disorder. In total, 71 peptides generated from 39 different proteins were found to be significantly altered in IC\/BPS. Five urinary peptides with high variable importance in projection (VIP) coefficients were found to reliably differentiate IC\/BPS from healthy controls by receiver operating characteristic (ROC) analysis. In parallel, we also developed a targeted multiple reaction monitoring method to quantify the relative abundance of the APF peptide from patient urine samples. Although the APF peptide was found in moderately higher abundance in IC\/BPS relative to control urine, our results show that the APF peptide was inconsistently present in urine, suggesting that its utility as a sole biomarker of IC\/BPS may be limited. Overall, our results revealed new insights into the profile of urinary peptides in IC\/BPS that will aid in future biomarker discovery and validation efforts.<\/jats:p>","DOI":"10.1038\/s41598-022-12197-2","type":"journal-article","created":{"date-parts":[[2022,5,18]],"date-time":"2022-05-18T13:03:13Z","timestamp":1652878993000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Peptidomics analysis reveals changes in small urinary peptides in patients with interstitial cystitis\/bladder pain syndrome"],"prefix":"10.1038","volume":"12","author":[{"given":"Md Shadman Ridwan","family":"Abid","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haowen","family":"Qiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bridget A.","family":"Tripp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aline","family":"de Lima Leite","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heidi E.","family":"Roth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiri","family":"Adamec","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Powers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James W.","family":"Checco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,5,18]]},"reference":[{"key":"12197_CR1","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1111\/iju.13118","volume":"23","author":"Y Homma","year":"2016","unstructured":"Homma, Y. et al. Clinical guidelines for interstitial cystitis and hypersensitive bladder updated in 2015. Int. J. Urol. 23, 542\u2013549 (2016).","journal-title":"Int. J. Urol."},{"key":"12197_CR2","doi-asserted-by":"publisher","first-page":"1341","DOI":"10.1007\/s00404-017-4364-2","volume":"295","author":"SS Patnaik","year":"2017","unstructured":"Patnaik, S. S. et al. Etiology, pathophysiology and biomarkers of interstitial cystitis\/painful bladder syndrome. Arch. Gynecol. Obstet. 295, 1341\u20131359 (2017).","journal-title":"Arch. Gynecol. Obstet."},{"key":"12197_CR3","doi-asserted-by":"publisher","first-page":"2057","DOI":"10.1007\/s40265-015-0504-9","volume":"75","author":"S Belknap","year":"2015","unstructured":"Belknap, S., Blalock, E. & Erickson, D. The challenges of interstitial cystitis: Current status and future prospects. Drugs 75, 2057\u20132063 (2015).","journal-title":"Drugs"},{"key":"12197_CR4","doi-asserted-by":"publisher","first-page":"13","DOI":"10.5213\/inj.1632522.261","volume":"20","author":"HJ Kim","year":"2016","unstructured":"Kim, H. J. Update on the pathology and diagnosis of interstitial cystitis\/bladder pain syndrome: A review. Int. Neurourol. J. 20, 13\u201317 (2016).","journal-title":"Int. Neurourol. J."},{"key":"12197_CR5","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1016\/j.maturitas.2009.09.016","volume":"64","author":"J Dasgupta","year":"2009","unstructured":"Dasgupta, J. & Tincello, D. G. Interstitial cystitis\/bladder pain syndrome: An update. Maturitas 64, 212\u2013217 (2009).","journal-title":"Maturitas"},{"key":"12197_CR6","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1016\/S0022-5347(05)67376-4","volume":"164","author":"YL Michael","year":"2000","unstructured":"Michael, Y. L., Kawachi, I., Stampfer, M. J., Colditz, G. A. & Curhan, G. C. Quality of life among women with interstitial cystitis. J. Urol. 164, 423\u2013427 (2000).","journal-title":"J. Urol."},{"key":"12197_CR7","doi-asserted-by":"publisher","first-page":"926","DOI":"10.1002\/nau.23421","volume":"37","author":"LC McKernan","year":"2018","unstructured":"McKernan, L. C. et al. Psychosocial co-morbidities in interstitial cystitis\/bladder pain syndrome (IC\/BPS): A systematic review. Neurourol. Urodyn. 37, 926\u2013941 (2018).","journal-title":"Neurourol. Urodyn."},{"key":"12197_CR8","doi-asserted-by":"publisher","first-page":"776","DOI":"10.1016\/j.urology.2007.11.154","volume":"71","author":"JQ Clemens","year":"2008","unstructured":"Clemens, J. Q., Meenan, R. T., Rosetti, M. C., Kimes, T. & Calhoun, E. A. Costs of interstitial cystitis in a managed care population. Urology 71, 776\u2013780 (2008).","journal-title":"Urology"},{"key":"12197_CR9","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1097\/01.ju.0000165170.43617.be","volume":"174","author":"JQ Clemens","year":"2005","unstructured":"Clemens, J. Q. et al. Prevalence of interstitial cystitis symptoms in a managed care population. J. Urol. 174, 576\u2013580 (2005).","journal-title":"J. Urol."},{"key":"12197_CR10","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1016\/j.urology.2006.05.050","volume":"69","author":"JK Parsons","year":"2007","unstructured":"Parsons, J. K., Kurth, K. & Sant, G. R. Epidemiologic issues in interstitial cystitis. Urology 69, 5\u20138 (2007).","journal-title":"Urology"},{"key":"12197_CR11","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1177\/1756287211398255","volume":"3","author":"S Grover","year":"2011","unstructured":"Grover, S., Srivastava, A., Lee, R., Tewari, A. K. & Te, A. E. Role of inflammation in bladder function and interstitial cystitis. Ther. Adv. Urol. 3, 19\u201333 (2011).","journal-title":"Ther. Adv. Urol."},{"key":"12197_CR12","unstructured":"Schaeffer, A., Freeman, M., Atala, A., Assimos, D., Burnett, A., Chacko, S., Chai, T., Evans, C., Getzenberg, R., Hanno, P., Hultgren, S., Lamb, D., Penson, D., Steers, W. & Wessels, H. Urology Care Foundation National Urology Research Agenda: 2010 (NURA) (2010)."},{"key":"12197_CR13","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1016\/j.juro.2010.06.046","volume":"184","author":"AJ Schaeffer","year":"2010","unstructured":"Schaeffer, A. J., Freeman, M. & Giambarresi, L. Introduction to the national urology research agenda: A roadmap for priorities in urological disease research. J. Urol. 184, 823\u2013824 (2010).","journal-title":"J. Urol."},{"key":"12197_CR14","doi-asserted-by":"publisher","first-page":"159","DOI":"10.5213\/inj.2012.16.4.159","volume":"16","author":"S You","year":"2012","unstructured":"You, S., Yang, W., Anger, J. T., Freeman, M. R. & Kim, J. \u201cOmics\u201d approaches to understanding interstitial cystitis\/painful bladder syndrome\/bladder pain syndrome. Int. Neurourol. J. 16, 159\u2013168 (2012).","journal-title":"Int. Neurourol. J."},{"key":"12197_CR15","first-page":"87","volume":"12","author":"S Argade","year":"2016","unstructured":"Argade, S., Chermansky, C. & Tyagi, P. Biomarkers for interstitial cystitis\/painful bladder syndrome. Womens Health 12, 87\u201390 (2016).","journal-title":"Womens Health"},{"key":"12197_CR16","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1186\/s12894-016-0129-7","volume":"16","author":"Z Chen","year":"2016","unstructured":"Chen, Z. & Kim, J. Urinary proteomics and metabolomics studies to monitor bladder health and urological diseases. BMC Urol. 16, 11 (2016).","journal-title":"BMC Urol."},{"key":"12197_CR17","doi-asserted-by":"publisher","first-page":"3806","DOI":"10.1016\/j.jchromb.2009.09.025","volume":"877","author":"Y Fukui","year":"2009","unstructured":"Fukui, Y., Kato, M., Inoue, Y., Matsubara, A. & Itoh, K. A metabonomic approach identifies human urinary phenylacetylglutamine as a novel marker of interstitial cystitis. J. Chromatogr. B Anal. Technol. Biomed. Life Sci. 877, 3806\u20133812 (2009).","journal-title":"J. Chromatogr. B Anal. Technol. Biomed. Life Sci."},{"key":"12197_CR18","doi-asserted-by":"publisher","DOI":"10.1038\/srep39227","volume":"6","author":"T Kind","year":"2016","unstructured":"Kind, T. et al. Interstitial cystitis-associated urinary metabolites identified by mass-spectrometry based metabolomics analysis. Sci. Rep. 6, 39227 (2016).","journal-title":"Sci. Rep."},{"key":"12197_CR19","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1016\/j.ebiom.2016.03.040","volume":"7","author":"KS Parker","year":"2016","unstructured":"Parker, K. S. et al. Urinary metabolomics identifies a molecular correlate of interstitial cystitis\/bladder pain syndrome in a multidisciplinary approach to the study of chronic pelvic pain (MAPP) research network cohort. EBioMedicine 7, 167\u2013174 (2016).","journal-title":"EBioMedicine"},{"key":"12197_CR20","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1021\/pr5007729","volume":"14","author":"H Wen","year":"2015","unstructured":"Wen, H. et al. Urinary metabolite profiling combined with computational analysis predicts interstitial cystitis-associated candidate biomarkers. J. Proteome Res. 14, 541\u2013548 (2015).","journal-title":"J. Proteome Res."},{"key":"12197_CR21","doi-asserted-by":"publisher","first-page":"553.e551","DOI":"10.1016\/j.ajog.2008.01.052","volume":"198","author":"MP Canter","year":"2008","unstructured":"Canter, M. P. et al. Proteomic techniques identify urine proteins that differentiate patients with interstitial cystitis from asymptomatic control subjects. Am. J. Obstet. Gynecol. 198, 553.e551-556 (2008).","journal-title":"Am. J. Obstet. Gynecol."},{"key":"12197_CR22","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1590\/S1677-55382010000400010","volume":"36","author":"YA Goo","year":"2010","unstructured":"Goo, Y. A., Tsai, Y. S., Liu, A. Y., Goodlett, D. R. & Yang, C. C. Urinary proteomics evaluation in interstitial cystitis\/painful bladder syndrome: A pilot study. Int. Braz. J. Urol. 36, 464\u2013478 (2010).","journal-title":"Int. Braz. J. Urol."},{"key":"12197_CR23","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1080\/00365590802025881","volume":"42","author":"S Kuromitsu","year":"2008","unstructured":"Kuromitsu, S. et al. Increased concentration of neutrophil elastase in urine from patients with interstitial cystitis. Scand. J. Urol. Nephrol. 42, 455\u2013461 (2008).","journal-title":"Scand. J. Urol. Nephrol."},{"key":"12197_CR24","doi-asserted-by":"publisher","first-page":"2112","DOI":"10.1016\/S0022-5347(05)66980-7","volume":"164","author":"S Keay","year":"2000","unstructured":"Keay, S., Kleinberg, M., Zhang, C. O., Hise, M. K. & Warren, J. W. Bladder epithelial cells from patients with interstitial cystitis produce an inhibitor of heparin-binding epidermal growth factor-like growth factor production. J. Urol. 164, 2112\u20132118 (2000).","journal-title":"J. Urol."},{"key":"12197_CR25","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/S0090-4295(01)01127-X","volume":"57","author":"SK Keay","year":"2001","unstructured":"Keay, S. K. et al. Sensitivity and specificity of antiproliferative factor, heparin-binding epidermal growth factor-like growth factor, and epidermal growth factor as urine markers for interstitial cystitis. Urology 57, 9\u201314 (2001).","journal-title":"Urology"},{"key":"12197_CR26","doi-asserted-by":"publisher","first-page":"1278","DOI":"10.1016\/S0090-4295(03)00005-0","volume":"61","author":"S Keay","year":"2003","unstructured":"Keay, S., Zhang, C. O., Shoenfelt, J. L. & Chai, T. C. Decreased in vitro proliferation of bladder epithelial cells from patients with interstitial cystitis. Urology 61, 1278\u20131284 (2003).","journal-title":"Urology"},{"key":"12197_CR27","doi-asserted-by":"publisher","first-page":"11803","DOI":"10.1073\/pnas.0404509101","volume":"101","author":"SK Keay","year":"2004","unstructured":"Keay, S. K. et al. An antiproliferative factor from interstitial cystitis patients is a frizzled 8 protein-related sialoglycopeptide. Proc. Natl. Acad. Sci. U.S.A. 101, 11803\u201311808 (2004).","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"12197_CR28","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1186\/1471-2490-4-3","volume":"4","author":"HH Rashid","year":"2004","unstructured":"Rashid, H. H. et al. Interstitial cystitis antiproliferative factor (APF) as a cell-cycle modulator. BMC Urol. 4, 3 (2004).","journal-title":"BMC Urol."},{"key":"12197_CR29","doi-asserted-by":"publisher","first-page":"37836","DOI":"10.1074\/jbc.M604581200","volume":"281","author":"TP Conrads","year":"2006","unstructured":"Conrads, T. P. et al. CKAP4\/p63 is a receptor for the frizzled-8 protein-related antiproliferative factor from interstitial cystitis patients. J. Biol. Chem. 281, 37836\u201337843 (2006).","journal-title":"J. Biol. Chem."},{"key":"12197_CR30","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1186\/s12858-017-0088-y","volume":"18","author":"B Chavda","year":"2017","unstructured":"Chavda, B., Ling, J., Majernick, T. & Planey, S. L. Antiproliferative factor (APF) binds specifically to sites within the cytoskeleton-associated protein 4 (CKAP4) extracellular domain. BMC Biochem. 18, 13 (2017).","journal-title":"BMC Biochem."},{"key":"12197_CR31","doi-asserted-by":"publisher","first-page":"1052","DOI":"10.1373\/clinchem.2013.211714","volume":"60","author":"JM Bauca","year":"2014","unstructured":"Bauca, J. M., Martinez-Morillo, E. & Diamandis, E. P. Peptidomics of urine and other biofluids for cancer diagnostics. Clin. Chem. 60, 1052\u20131061 (2014).","journal-title":"Clin. Chem."},{"key":"12197_CR32","doi-asserted-by":"publisher","first-page":"2424","DOI":"10.1074\/mcp.M110.001917","volume":"9","author":"DM Good","year":"2010","unstructured":"Good, D. M. et al. Naturally occurring human urinary peptides for use in diagnosis of chronic kidney disease. Mol. Cell. Proteomics 9, 2424\u20132437 (2010).","journal-title":"Mol. Cell. Proteomics"},{"key":"12197_CR33","doi-asserted-by":"publisher","first-page":"1242","DOI":"10.1038\/s41598-020-58067-7","volume":"10","author":"LA Brondani","year":"2020","unstructured":"Brondani, L. A. et al. Urinary peptidomics and bioinformatics for the detection of diabetic kidney disease. Sci. Rep. 10, 1242 (2020).","journal-title":"Sci. Rep."},{"key":"12197_CR34","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/1559-0275-11-7","volume":"11","author":"TK Sigdel","year":"2014","unstructured":"Sigdel, T. K. et al. Optimization for peptide sample preparation for urine peptidomics. Clin. Proteomics 11, 7 (2014).","journal-title":"Clin. Proteomics"},{"key":"12197_CR35","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1002\/mas.20079","volume":"25","author":"LD Fricker","year":"2006","unstructured":"Fricker, L. D., Lim, J., Pan, H. & Che, F. Y. Peptidomics: Identification and quantification of endogenous peptides in neuroendocrine tissues. Mass Spectrom. Rev. 25, 327\u2013344 (2006).","journal-title":"Mass Spectrom. Rev."},{"key":"12197_CR36","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1016\/j.tips.2015.05.009","volume":"36","author":"EV Romanova","year":"2015","unstructured":"Romanova, E. V. & Sweedler, J. V. Peptidomics for the discovery and characterization of neuropeptides and hormones. Trends Pharmacol. Sci. 36, 579\u2013586 (2015).","journal-title":"Trends Pharmacol. Sci."},{"key":"12197_CR37","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1021\/pr020010u","volume":"2","author":"M Svensson","year":"2003","unstructured":"Svensson, M., Skold, K., Svenningsson, P. & Andren, P. E. Peptidomics-based discovery of novel neuropeptides. J. Proteome Res. 2, 213\u2013219 (2003).","journal-title":"J. Proteome Res."},{"key":"12197_CR38","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1007\/978-1-60761-535-4_17","volume":"615","author":"RM Sturm","year":"2010","unstructured":"Sturm, R. M., Dowell, J. A. & Li, L. Rat brain neuropeptidomics: Tissue collection, protease inhibition, neuropeptide extraction, and mass spectrometric analysis. Methods Mol. Biol. 615, 217\u2013226 (2010).","journal-title":"Methods Mol. Biol."},{"key":"12197_CR39","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1155\/2004\/530647","volume":"19","author":"QN Van","year":"2003","unstructured":"Van, Q. N. et al. The use of urine proteomic and metabonomic patterns for the diagnosis of interstitial cystitis and bacterial cystitis. Dis. Markers 19, 169\u2013183 (2003).","journal-title":"Dis. Markers"},{"key":"12197_CR40","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1186\/1471-2490-14-57","volume":"14","author":"JQ Clemens","year":"2014","unstructured":"Clemens, J. Q. et al. The MAPP research network: A novel study of urologic chronic pelvic pain syndromes. BMC Urol. 14, 57 (2014).","journal-title":"BMC Urol."},{"key":"12197_CR41","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1186\/1471-2490-14-58","volume":"14","author":"JR Landis","year":"2014","unstructured":"Landis, J. R. et al. The MAPP research network: Design, patient characterization and operations. BMC Urol. 14, 58 (2014).","journal-title":"BMC Urol."},{"key":"12197_CR42","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1016\/j.urology.2009.06.078","volume":"74","author":"JQ Clemens","year":"2009","unstructured":"Clemens, J. Q. et al. Validation of a modified National Institutes of Health chronic prostatitis symptom index to assess genitourinary pain in both men and women. Urology 74, 983\u2013987 (2009).","journal-title":"Urology"},{"key":"12197_CR43","doi-asserted-by":"publisher","first-page":"2337","DOI":"10.1002\/rcm.1196","volume":"17","author":"B Ma","year":"2003","unstructured":"Ma, B. et al. PEAKS: Powerful software for peptide de novo sequencing by tandem mass spectrometry. Rapid Commun. Mass Spectrom. 17, 2337\u20132342 (2003).","journal-title":"Rapid Commun. Mass Spectrom."},{"issue":"M111","key":"12197_CR44","volume":"11","author":"J Zhang","year":"2012","unstructured":"Zhang, J. et al. PEAKS DB: De novo sequencing assisted database search for sensitive and accurate peptide identification. Mol. Cell. Proteomics 11(M111), 010587 (2012).","journal-title":"Mol. Cell. Proteomics"},{"key":"12197_CR45","doi-asserted-by":"publisher","first-page":"D480","DOI":"10.1093\/nar\/gkaa1100","volume":"49","author":"UniProt Consortium","year":"2021","unstructured":"UniProt Consortium. UniProt: The universal protein knowledgebase in 2021. Nucleic Acids Res. 49, D480\u2013D489 (2021).","journal-title":"Nucleic Acids Res."},{"key":"12197_CR46","doi-asserted-by":"crossref","unstructured":"Cover, T. & Hart, P. Nearest neighbor pattern classification. IEEE Trans. Inf. Theory, 21\u201327 (1967).","DOI":"10.1109\/TIT.1967.1053964"},{"key":"12197_CR47","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0116221","volume":"9","author":"YV Karpievitch","year":"2014","unstructured":"Karpievitch, Y. V., Nikolic, S. B., Wilson, R., Sharman, J. E. & Edwards, L. M. Metabolomics data normalization with EigenMS. PLoS\u00a0One 9, e116221 (2014).","journal-title":"PLoS\u00a0One"},{"key":"12197_CR48","doi-asserted-by":"publisher","first-page":"2573","DOI":"10.1093\/bioinformatics\/btp426","volume":"25","author":"YV Karpievitch","year":"2009","unstructured":"Karpievitch, Y. V. et al. Normalization of peak intensities in bottom-up MS-based proteomics using singular value decomposition. Bioinformatics 25, 2573\u20132580 (2009).","journal-title":"Bioinformatics"},{"key":"12197_CR49","unstructured":"RStudioTeam. RStudio: Integrated Development for R (2021)."},{"key":"12197_CR50","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1111\/j.2517-6161.1995.tb02031.x","volume":"57","author":"Y Benjamini","year":"1995","unstructured":"Benjamini, Y. & Hochberg, Y. Controlling the false discovery rate: A practical and powerful approach to multiple testing. J. R. Stat. Soc. Ser. B 57, 289\u2013300 (1995).","journal-title":"J. R. Stat. Soc. Ser. B"},{"key":"12197_CR51","doi-asserted-by":"publisher","first-page":"3322","DOI":"10.1021\/acs.jproteome.5b00354","volume":"14","author":"EA Th\u00e9venot","year":"2015","unstructured":"Th\u00e9venot, E. A., Roux, A., Xu, Y., Ezan, E. & Junot, C. Analysis of the human adult urinary metabolome variations with age, body mass index, and gender by implementing a comprehensive workflow for univariate and OPLS statistical analyses. J. Proteome Res. 14, 3322\u20133335 (2015).","journal-title":"J. Proteome Res."},{"key":"12197_CR52","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1002\/cem.785","volume":"17","author":"M Barker","year":"2003","unstructured":"Barker, M. & Rayens, W. Partial least squares for discrimination. J. Chemom. 17, 166\u2013173 (2003).","journal-title":"J. Chemom."},{"key":"12197_CR53","doi-asserted-by":"publisher","first-page":"1164","DOI":"10.1093\/bioinformatics\/btm069","volume":"23","author":"W Stacklies","year":"2007","unstructured":"Stacklies, W., Redestig, H., Scholz, M., Walther, D. & Selbig, J. pcaMethods\u2014A bioconductor package providing PCA methods for incomplete data. Bioinformatics 23, 1164\u20131167 (2007).","journal-title":"Bioinformatics"},{"key":"12197_CR54","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1016\/S0001-2998(78)80014-2","volume":"8","author":"CE Metz","year":"1978","unstructured":"Metz, C. E. Basic principles of ROC analysis. Semin. Nucl. Med. 8, 283\u2013298 (1978).","journal-title":"Semin. Nucl. Med."},{"key":"12197_CR55","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1097\/00005392-199907000-00030","volume":"162","author":"A Rosamilia","year":"1999","unstructured":"Rosamilia, A., Clements, J. A., Dwyer, P. L., Kende, M. & Campbell, D. J. Activation of the kallikrein kinin system in interstitial cystitis. J. Urol. 162, 129\u2013134 (1999).","journal-title":"J. Urol."},{"key":"12197_CR56","doi-asserted-by":"publisher","first-page":"874","DOI":"10.1016\/S0022-5347(17)32595-8","volume":"152","author":"BL Zuraw","year":"1994","unstructured":"Zuraw, B. L. et al. Activation of urinary kallikrein in patients with interstitial cystitis. J. Urol. 152, 874\u2013878 (1994).","journal-title":"J. Urol."},{"key":"12197_CR57","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1111\/j.1464-410X.1995.tb07840.x","volume":"76","author":"W Boucher","year":"1995","unstructured":"Boucher, W., el-Mansoury, M., Pang, X., Sant, G. R. & Theoharides, T. C. Elevated mast cell tryptase in the urine of patients with interstitial cystitis. Br. J. Urol. 76, 94\u2013100 (1995).","journal-title":"Br. J. Urol."},{"key":"12197_CR58","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1016\/S0022-5347(01)61915-3","volume":"161","author":"AJ Okragly","year":"1999","unstructured":"Okragly, A. J. et al. Elevated tryptase, nerve growth factor, neurotrophin-3 and glial cell line-derived neurotrophic factor levels in the urine of interstitial cystitis and bladder cancer patients. J. Urol. 161, 438\u2013441 (1999).","journal-title":"J. Urol."},{"key":"12197_CR59","doi-asserted-by":"publisher","first-page":"2387","DOI":"10.3389\/fimmu.2018.02387","volume":"9","author":"Z Fu","year":"2018","unstructured":"Fu, Z., Thorpe, M., Akula, S., Chahal, G. & Hellman, L. T. Extended cleavage specificity of human neutrophil elastase, human proteinase 3, and their distant ortholog clawed frog PR3-three elastases with similar primary but different extended specificities and stability. Front. Immunol. 9, 2387 (2018).","journal-title":"Front. Immunol."},{"key":"12197_CR60","doi-asserted-by":"publisher","first-page":"670","DOI":"10.1111\/j.1464-410X.2010.09500.x","volume":"107","author":"SI Lemberger","year":"2011","unstructured":"Lemberger, S. I. et al. Decrease of Trefoil factor 2 in cats with feline idiopathic cystitis. BJU Int. 107, 670\u2013677 (2011).","journal-title":"BJU Int."},{"key":"12197_CR61","doi-asserted-by":"publisher","first-page":"4077","DOI":"10.1158\/1078-0432.CCR-15-2715","volume":"22","author":"M Frantzi","year":"2016","unstructured":"Frantzi, M. et al. Development and validation of urine-based peptide biomarker panels for detecting bladder cancer in a multi-center study. Clin. Cancer Res. 22, 4077\u20134086 (2016).","journal-title":"Clin. Cancer Res."},{"key":"12197_CR62","doi-asserted-by":"publisher","first-page":"5974","DOI":"10.1021\/jm8002763","volume":"51","author":"P Kaczmarek","year":"2008","unstructured":"Kaczmarek, P. et al. Structure\u2013activity relationship studies for the peptide portion of the bladder epithelial cell antiproliferative factor from interstitial cystitis patients. J. Med. Chem. 51, 5974\u20135983 (2008).","journal-title":"J. Med. Chem."},{"key":"12197_CR63","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1021\/ml100087a","volume":"1","author":"P Kaczmarek","year":"2010","unstructured":"Kaczmarek, P. et al. Structure\u2013activity studies on antiproliferative factor (APF) glycooctapeptide derivatives. ACS Med. Chem. Lett. 1, 390\u2013394 (2010).","journal-title":"ACS Med. Chem. Lett."},{"key":"12197_CR64","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1007\/978-1-4939-9488-5_19","volume":"1996","author":"F Bhinderwala","year":"2019","unstructured":"Bhinderwala, F. et al. Metabolomics analyses from tissues in Parkinson\u2019s disease. Methods Mol. Biol. 1996, 217\u2013257 (2019).","journal-title":"Methods Mol. Biol."},{"key":"12197_CR65","doi-asserted-by":"publisher","first-page":"684","DOI":"10.1021\/cb300673e","volume":"8","author":"T Gebregiworgis","year":"2013","unstructured":"Gebregiworgis, T. et al. Potential of urinary metabolites for diagnosing multiple sclerosis. ACS Chem. Biol. 8, 684\u2013690 (2013).","journal-title":"ACS Chem. Biol."},{"key":"12197_CR66","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1021\/acs.jproteome.5b01111","volume":"15","author":"T Gebregiworgis","year":"2016","unstructured":"Gebregiworgis, T. et al. A urinary metabolic signature for multiple sclerosis and neuromyelitis optica. J. Proteome Res. 15, 659\u2013666 (2016).","journal-title":"J. Proteome Res."},{"key":"12197_CR67","doi-asserted-by":"publisher","first-page":"1138","DOI":"10.1021\/cb4008937","volume":"9","author":"B Worley","year":"2014","unstructured":"Worley, B. & Powers, R. MVAPACK: A complete data handling package for NMR metabolomics. ACS Chem. Biol. 9, 1138\u20131144 (2014).","journal-title":"ACS Chem. Biol."},{"key":"12197_CR68","doi-asserted-by":"publisher","first-page":"D543","DOI":"10.1093\/nar\/gkab1038","volume":"50","author":"Y Perez-Riverol","year":"2022","unstructured":"Perez-Riverol, Y. et al. The PRIDE database resources in 2022: A hub for mass spectrometry-based proteomics evidences. Nucleic Acids Res. 50, D543-d552 (2022).","journal-title":"Nucleic Acids Res."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-12197-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-12197-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-12197-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,25]],"date-time":"2024-09-25T10:16:20Z","timestamp":1727259380000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-12197-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,18]]},"references-count":68,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["12197"],"URL":"https:\/\/doi.org\/10.1038\/s41598-022-12197-2","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,5,18]]},"assertion":[{"value":"23 February 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 May 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 May 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"8289"}}